X0202 3 2005-09-20 0 0001086688 INTARCIA THERAPEUTICS, INC ITCA 0001276361 ALTA PARTNERS II INC ONE EMBARCADERO CENTER SUITE 4050 SAN FRANCISCO CA 94111 0 0 1 0 0001163189 ALTA BIOPHARMA MANAGEMENT II LLC ONE EMBARCADERO CENTER SUITE 4050 SAN FRANCISCO CA 94111 0 0 1 0 0001163157 ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC ONE EMBARCADERO CENTER SUITE 4050 SAN FRANCISCO CA 94111 0 0 1 0 0001198321 CHAMPSI FARAH ONE EMBARCADERO CENTER SUITE 4050 SAN FRANCISCO CA 94111 0 0 1 0 0001338944 Alta California Management Partners II, LLC -- New Pool ONE EMBARCADERO CENTER SUITE 4050 SAN FRANCISCO CA 94111 0 0 1 0 0001163156 ALTA BIOPHARMA PARTNERS II LP ONE EMBARCADERO CENTER SUITE 4050 SAN FRANCISCO CA 94111 0 0 1 0 Series B Preferred Stock Common Stock 388888 I See Footnotes Series C Preferred Stock Common Stock 130207 I See Footnotes Series D Preferred Stock Common Stock 1909721 I See Footnotes Series E Preferred Stock Common Stock 1470586 I See Footnotes Immediately N/A The Series B Preferred Stock is convertible into Common Stock on a 1:0.25 basis. Alta Partners ("AP") provides investment advisory services to several venture capital funds including, Alta California Partners II, L.P. ("ACPII"), Alta Embarcadero Partners II, LLC ("AEPII") & Alta California Partners II, L.P.-New Pool ("ACPIINP"). ACPII beneficially owns 1,541,305 shares ("sh") of Series B Preferred Stock ("Ser B"), 314,098 sh Series C Preferred Stock ("Ser C"), 2,057,341 sh Series D Preferred Stock ("Ser D") & 1,936,322 sh Series E Preferred Stock ("Ser E"). AEPII beneficially owns 14,251 sh Ser B, 3,968 sh Ser C, 25,992 sh Ser D & 24,463 sh Ser E. ACPIINP beneficially owns 5,882,353 sh Ser E. The respective general partners, members & managing directors of ACPII, AEPII & ACPIINP exercise sole voting & investment power with respect to the shares owned by such funds. Alta Partners II, Inc. ("APII") provides investment advisory services to several venture capital funds including, Alta BioPharma Partners II, L.P. ("ABPII") & Alta Embarcadero BioPharma Partners II, LLC ("AEBPII"). ABPII beneficially owns 20,094,126 shares ("sh") of Series D Preferred Stock ("Ser D") & 9,456,059 sh of Series E Preferred Stock ("Ser E"). AEPII beneficially owns 739,208 sh Ser D & 347,863 sh of Ser E. The respective general partners, managing directors & managers of ABPII & AEBPII exercise sole voting & investment power with respect to the shares owned by such funds. Jean Deleage, Guy Nohra, Garrett Gruener, Daniel Janney & Alix Marduel (collectively known as the "principals") of Alta Partners ("AP") are members of Alta California Management Partners II, LLC & Alta California Management Partners II- New Pool, LLC (which are the general partners of Alta California Partners II, L.P. & Alta California Partners II, L.P.-New Pool respectively), & members of Alta Embarcadero Partners II, LLC. As members of such funds, they may be deemed to share voting & investment powers for the shares held by the funds. The principals of AP disclaim beneficial ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein. Jean Deleage, Director, is a member of Alta California Management Partners II, LLC (which is the general partner of Alta California Partners II, L.P. & Alta California Partners II, L.P.- New Pool), a member of Alta Embarcadero Partners II, LLC, a managing director of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.), and a manager of Alta Embarcadero BioPharma Partners II, LLC. As a member, managing director and manager he may be deemed to share voting and investment powers for the shares held by the funds. He disclaims beneficial ownership of all such shares held by the foregoing funds, except to the extent of his proportionate pecuniary interest therein. Jean Deleage, Alix Marduel and Farah Champsi (collectively known as the "principals") of Alta Partners II, Inc. ("APII") are managing directors of Alta BioPharma Management II, LLC (which is the general partner of Alta BioPharma Partners II, L.P.) and managers of Alta Embarcadero BioPharma Partners II, LLC. As managing directors & managers of such funds, they may be deemed to share voting & investment powers for the shares held by the foregoing funds. The principals of APII disclaim benefical ownership of all such shares held by the foregoing funds, except to the extent of their proportionate pecuniary interests therein. The Series C Preferred Stock is convertible into Common Stock on a 1:0.409375 basis. The Series D Preferred Stock and the Series E Preferred Stock are convertible into Common Stock on a 1:0.0833333 basis. Cross-reference with Form 3 filed on behalf of Jean Deleage dated 9/20/2005. Jean Deleage, President 2005-09-20 Farah Champsi, Managing Director 2005-09-20 Farah Champsi, Manager 2005-09-20 Farah Champsi 2005-09-20 Alix Marduel, Member 2005-09-20 Farah Champsi, Managing Director 2005-09-20